be communicated and explains the reasons for those recommendations. Doing so not only informs authors about what to write, but also informs readers and referees about what to look for in a good paper. Secondarily, the article publicizes examples of errors and deficiencies of manuscripts submitted to the Journal in the past that have delayed their acceptance and publication, which could have been avoided had the forthcoming recommendations been followed. The recommendations also reprise the elements taught in courses conducted by the Spine Intervention Society in their extended program on evidence-based medicine. Doing so underscores that instructions for authors are not a procedural technicality but a way to ensure that what authors write, what readers read, and what the Journal publishes comply with contemporary precepts of good evidence.
Some 20 years ago, the Journal of the American Medical Association published a comprehensive series of articles with a common title: "Users' Guides to the Medical Literature" [1, 2] . These articles focused on the science of statistical tests and critical appraisal, and their importance for properly understanding the literature. The present article differs in that it does not presume to teach technicalities. Instead, it describes and explains, step by step, the critical components of an article, what authors should include, and what readers should look for, so that the Journal can ensure that consistent, high-quality information is shared between its authors and readers.
Introduction
The Introduction of a paper should explain and justify why the study was undertaken. This should be achieved succinctly. Indeed, a good Introduction is defined more by what it should not include rather than what it should include.
An Introduction should not be a comprehensive review of the literature, or even a contracted version of such a review. If the topic is, say, the results of a new treatment for discogenic pain, the Introduction does not need to start with a description of the lumbar spine. Nor does it need to summarize the history of all attempts to treat discogenic pain. The objective is to reach promptly the question being addressed. This can be done in about three steps: a brief overview of the topic in general, a description of the current state of the art, including the questions that need answers, and a statement of how the present study addresses a particular question or questions.
The opening sentence should not be banal or a cliché . Too many papers commence with an equivalent of: "Back pain is a large problem." Authors should strive to compose an opening sentence that captures the interest of the reader and heralds the theme of the ensuing paper.
The final paragraph of the Introduction should be decisive, not biographical. Journals are not interested in publishing biographical accounts whose Introduction concludes with no more than: "We share with readers our experience with this procedure." The study being introduced should contribute to the advancement of Science by providing a decisive answer to a pertinent question. Preferred are studies that address high-order questions such as: "Is this treatment more effective than sham treatment, to a clinically significant degree?" However, there can be a role for lower-order contributions, such as: "In conventional practice, could we reproduce the outcomes reported in previous studies?" or "Does this new treatment appear at all to be effective in a worthwhile proportion of patients?"
An important philosophical principle is that no study can prove efficacy. Positive conjectures cannot be proven [3] . Science progresses by the refutation of null hypotheses [3] . Therefore, the objective of a study cannot be cast as: "to prove that this treatment is effective." The correct objective is a null hypothesis that can be tested statistically, such as: "to test if this treatment was no more effective than (something else)."
For observational studies, such a decisive hypothesis is not available, hence the limited value of observational studies in progressing Science. Nevertheless, observational studies can still answer useful questions such as: "Does this treatment achieve clinically significant outcomes in a clinically significant proportion of patients?" In this regard, if sensible definitions of "clinically significant" are proposed, the null hypothesis to be tested becomes: "This treatment does not work sufficiently often, or to a sufficient degree."
Methods
The Methods section should inform readers about how the study was conducted. Like a recipe, if followed, the Methods should allow readers to reproduce the study exactly. This involves more than just how the patients were treated and assessed.
For a clinical study, the Methods should start with a description of where the study was conducted. Readers want to know if the location of the study was like their own or differed significantly. Significant differences could apply between studies conducted in urban or rural environments, under different socioeconomic conditions, in different countries with different health systems, or different cultural environments that possibly affect patient expectations or responses to assessment.
A subset of location is the nature of the practice setting in which the study was conducted. The types of patients and the types of problems seen may differ between a private and public practice, a clinic or hospital setting, referred or self-referred patients, and between highly specialized or exclusive clinics and more generalized practices. These factors can affect the external validity (generalizability) of the outcomes and, so, should be announced in the Methods.
The date of a study can be important. Insights into a problem, means of diagnosis, or options for treatment may have been different when the study was conducted. This may be more important if and when the publication is referred to in the future, when medical science has advanced. So, the Methods should record: "This study was conducted between [date] and [date] ."
Early in the Methods is a convenient place to report ethics approval of study. Ethics approval is reassuring to readers, on the grounds that someone else thought about the study before it was conducted and assessed its integrity. Readers can be excused for feeling suspicious about a study if it has not had ethics approval from a respectable, independent entity. At this juncture, it is also appropriate to address the financial aspects of the study. This covers how the study was funded: whether by the patients, health care insurance, an independent research grant, or by corporate sponsorship. In particular, it should be disclosed if the authors had any financial interests in the treatment being studied and the extent to which external agencies may have had input in the conduct of the study or the analysis of its results. Perceptive readers will recognize that these factors could be serious sources of bias in the results.
At some stage early in the Methods, it should be announced if the study was prospective or retrospective and if consecutive patients were captured. This is an important courtesy to readers who appreciate the liabilities of retrospective studies. In a retrospective study, different types of patients may have been referred for treatment in the past (referral bias); patients may have been selected by different or less stringent criteria (selection bias); treated less expertly (treatment bias); assessed differently for outcomes (assessment bias); or all patients recruited for the study may not have been consecutive (reporting bias). Authors are not required formally to recognize or announce these biases, but later, in the Discussion, they do have a duty to explain how such biases may have affected the integrity of the results of their retrospective study.
Too often, authors launch prematurely into describing their sample. To perceptive readers, this begs the question: "Where did these patients come from?" Therefore, it is courteous, let alone informative, to describe the population from which the same was drawn. The "population" is the patients whom the authors see on an everyday basis, and before any selection criteria for the study are applied. The Methods should state the presenting features of the patients who constitute the population. Doing so provides for readers a baseline against which subsequently to estimate just how relevant the treatment in question is. An example of how to describe the population could be: "Patients for the present study were drawn from all patients referred to the clinic with back pain, and who agreed to undergo invasive diagnostic testing."
The derivation of the sample should then follow a logical and chronological sequence. Patients in the population are screened for possible inclusion in the study by the application of inclusion and exclusion criteria. The inclusion criteria might be two-tiered or more. Patients might have to satisfy certain clinical criteria before undergoing invasive investigations.
The inclusion criteria should be stipulated in chronological and hierarchical order. This means that if a given patient does not satisfy a first criterion they are immediately excluded, and subsequent criteria become immaterial. Importantly, the inclusion criteria should be reliable and valid. If the criteria are not self-evident or generally accepted, references should be provided for the attributes of reliability and validity of the criteria. Unless the criteria are reliable and valid, readers will not be convinced that the selection of patients was correct or that in their own hands they would be able to select the same patients.
Exclusion criteria are often and typically routine and selfexplanatory, such as comorbidity, pregnancy, infection, and coagulopathy. Under those conditions, it is not necessary to waste extensive prose to the description of exclusion criteria. If numerous, they can be conveniently listed in a table.
Having described the sample of patients selected for treatment, the Methods can proceed to describing the treatment applied. This need not be exhaustive if references are available to comprehensive descriptions of the treatment. Nevertheless, a brief synopsis of the key elements of the treatment should be provided for readers who might be less aware of the literature. For interventional procedures under image guidance, it is helpful to readers if authors illustrate their technique.
Assessment of outcome follows treatment. The Methods should describe in detail the domains to be assessed, the instruments used, and how they were applied.
Readers expect more than just data on pain. Relief of pain alone is not sufficient evidence of effectiveness if other variables are not improved. These other variables are not secondary outcomes, meaning of lesser importance; they are critical elements of outcome. Relief of pain becomes convincing if the patient improves function (or reduces disability), reduces the use of other health care, and is able to return to work if socially possible. Therefore, a minimal set of outcome domains should be pain, function (or disability), use of health care, and return to work. Others might be added, when relevant, for particular conditions or particular interventions, such as restoration of neurologic function or reduction in psychological distress. For each domain of assessment, validated instruments should be used. Perceptive readers will not trust ad hoc instruments that have not been validated. The case for validation does not have to be argued; references to instruments having been validated can suffice. For each instrument, the scale used should be stated so that readers can understand what the numbers mean: whether a high score or a low score means a good outcome. As well, a statement should be provided, with references, as to the minimum clinically important change, or minimal detectable change, for each instrument, plus other values if available, such as what degree of change patients consider really worthwhile or restorative. This will allow readers to gauge if the improvements achieved in the study are trivial, small, or substantial.
The Methods should describe how the assessment was conducted. Face-to-face interview is more convincing to readers because the assessor can verify visually features such as the mood of the patient and their physical function, and if these are consistent with their subjective responses. The data obtained should pertain to the condition of the patient at the time of assessment. Asking the patient how they were at some time in the past incurs the risk of recall bias.
The Methods should provide a statement as to who administers the instruments. Optimally this should be an independent assessor. Readers would be justified in being wary of assessments undertaken by the treating physician because of the combined risk of response bias (patients exaggerating their response in order to please the doctor) and observer bias (the physician amplifying the response in order to achieve better than actual results). If an independent assessor is not used, authors should be prepared to explain in their Discussion why this does not compromise their results.
Assessment should occur over a sustained period following treatment. There is no unique or special duration of follow-up that should be achieved, and it may differ for different conditions or different interventions, but it is not arbitrary. Follow-up should be long enough to answer the question posed by the study. The concern of readers is that if the duration of follow-up is too short, the reported success rate may be exaggerated because with longer follow-up outcomes might deteriorate. Therefore, one guideline is that patients should be followed until outcomes start to plateau, that is, cease deteriorating and stabilize, or until the half-life of effect can be calculated. For major interventions that cannot be repeated or that alter the patient's anatomy, a minimum of 12 months of follow-up is conventionally required in the first instance to determine if the investment in treatment is justified. Subsequently, this would need to be supplemented by longer-term follow-up to determine the rate of loss of effect.
A common flaw in studies is that patients are followed for different periods of time, and authors report a mean period of follow-up. This creates an illusion that the mean period stated somehow applies to all patients. It does not. A mean period of follow-up of, say, nine months, is not indicative of the duration of effect if many patients were followed for only one or two months. Under those conditions, the correct manner of reporting is to state the minimum duration of follow-up that every patient achieved. If all patients have not yet achieved, say, a six-month or 12-month follow-up, authors should delay submitting manuscripts until every patient has reached the intended time node.
A final component of the Methods is how the acquired data were handled statistically. For the most part, this requires stating the statistical tests that were applied and naming the statistical packages used for any complex calculations. For unusual or uncommon statistical tests, authors should offer readers the courtesy of briefly explaining what the test does and what its results mean.
It is customary to declare the thresholds used for statistically significant differences. Typically this is a P value of 0.05. In some types of study, more demanding P values apply. However, more important is the notion of clinical significance. In order to be clinically significant, differences may be substantially larger than those required to achieve statistical significance. Therefore, authors should define clinical significance for each outcome measure that they use.
Although group data (significant changes in mean scores or median scores) may indicate that a treatment is effective on the average, they do not reveal how particular patients respond or how many respond. Yet, this is what readers want to know. They want to know the success rate of the treatment. Therefore, the Methods need to relate how a successful outcome was defined and how it was calculated.
There is no unique or universally accepted definition of success. Some readers might accept a liberal definition; others might be more demanding. Meanwhile, authors should not insist that their own definition should apply and be the only one reported. Their data will not be convincing and will not be of use to readers who wish to apply a different definition. Therefore, a transparent report would provide data for a range of definitions. For the domain of pain, examples include the proportion of patients who achieve complete relief, the proportion who achieve at least 50% relief but not complete relief, and the proportion who achieve at least the minimum clinically important change. A more detailed and informative alternative is to report the number (and proportion) of patients who obtain different grades of relief in 10% bands from 0 to 100, including how many were worse after treatment. Analogous definitions can be formulated for other outcome measures.
An intention-to-treat analysis should be applied. The responses should be recorded of all patients who were allocated to a particular treatment, before and regardless of whether they changed to another treatment. Changing to another treatment implies that the first treatment failed, and the results should report this. n important courtesy to readers is that authors should not overstate their outcomes by ignoring patients who dropped out or were not followed. Perceptive readers will recognize that authors who ignore these patients are seeking to amplify their results. The convention is that a worst-case analysis should apply. The success rate is calculated by dividing the number of patients who achieved the prescribed outcome by the total number of patients who were treated (not the number who were finally followed). Doing so announces to readers that were they to adopt this treatment, they could expect a success rate no worse than the one reported.
Sample size is a particular issue. For trials in which two treatments are compared, it is customary to conduct a power calculation. This ensures that the sample size is sufficiently large to allow a difference to be detected if a difference in outcome is likely to occur. Power calculations serve to prevent a study being too small to draw a conclusion that would have been possible had a larger sample been used. Similar considerations, however, also apply to observational studies in which the cardinal result is the success rate of treatment. The sample size should be large enough to draw a meaningful conclusion. A success rate of 6/10 does not equal 60% because its 95% confidence intervals are 30% to 90%, and an observed success rate of 60% is not representative of a possible success rate as low as 30%. For observed success rates to be meaningful to readers, the confidence intervals need to be reasonably narrow, and authors should plan their sample size accordingly. A suitable subsequent guideline is that authors should not conclude that the indicative success rate of their treatment is the observed success rate; rather, the success rate that others can expect to incur is unlikely to be worse than the lower 95% confidence limit of the rate observed in the study.
Guidelines for Authors
If there are features of the patients in the sample to be studied that might significantly affect outcomes, authors should be prepared to stratify their outcome data. This means determining, and then reporting, the outcomes separately for different subgroups of patients. If statistical comparison later shows that the outcomes are equivalent, the two groups can legitimately be recombined; but if the outcomes are different, they must remain separated. In that event, the sample sizes of each subgroup will be reduced, and this may affect the confidence intervals of the observed success rates in each group. For those success rates to be meaningful and informative, the sample sizes of each subgroup need to be sufficiently large, and consequently the combined sample size may need to be larger than originally planned. Authors should not combine significantly different groups simply to create a larger sample size.
Results
The Results should tell readers what was found. This amounts to a statement of facts, without editorial comment or explanation. Nor should new methods be introduced late into the Results. All methods should appear in the Methods section. Otherwise, stylistically, the Results should echo the Methods in logical and chronological order.
The sample that was studied, and its recruitment, should be described. Tell readers how many patients were screened and how many satisfied the inclusion criteria to become eligible for inclusion in the study. Continue by reporting how many patients then agreed to participate, and report how many declined and the reasons why. These data are important to readers for they will want to know if the treatment in question is widely applicable or applicable only to highly selected patients.
Next describe the demographic features of the sample finally selected. These features should include conventional variables such as age and gender, but particularly they should include potentially confounding variables such as insurance status, medicolegal status, socioeconomic status, and work status. If unremarkable, these data can be conveyed in a table rather than wasting text. Text should be reserved for a brief statement about the demographic features being unremarkable, or only to draw attention to significant features.
A description of the clinical features of the sample should follow. These are best conveyed in a table, with the text being reserved for drawing attention to the important features. Essential are the duration of illness and any comorbidities that might affect outcomes. Duration of illness should be stratified into acute and chronic because the outcomes are likely to be different in each category. For research purposes, the recommended definition is that pain lasting less than six months is classified as acute; pain lasting longer than six months is chronic pain or persistent pain. When applicable, the segmental location of a diagnosis or the segmental location of the treatment should be stated. Sometimes it might be necessary to report which patients satisfied which diagnostic criteria, particularly when selection criteria are contentious or might be a source of bias.
An awkward issue pertains to reporting the baseline values of outcome variables: whether they are reported independently and before outcomes or reported together with outcome data so as to emphasize changes over time. Some readers consider baseline data to be critical elements of the clinical features of the sample and so expect them in the description of clinical features. It is probably wise to include summary statistics in that description so as to inform readers about the representative severity of pain and disability of the sample. More explicit data can be elaborated later in the context of outcomes and their change from inception to follow-up.
At this stage in the Results, it is usually convenient to announce the patients who dropped out of the study or did not reach the prescribed times of follow-up. The reasons for dropout or loss to follow-up should be provided. Sometimes it can be useful and informative to provide a statistical comparison of the baseline features of the patients who completed the study and those who did not, in case there are evident determining factors or factors that might bias the results. For example, it may be that patients who completed the study were ones with milder pain or ones of a different socioeconomic status.
It is also convenient to report any adverse effects before proceeding to report the outcomes. Doing so avoids interfering with the narrative in the subsequent text, which should highlight the outcomes.
State the primary outcomes for each outcome variable, for each group, and for each time node of follow-up. In the first instance, this should be a statement of the raw data, free of inference or statistical testing. The more detailed these data are, the more transparent will be the report, and the more informative it will be to readers.
For small studies, the most revealing display would be a table that lists the baseline data and follow-up data for each patient (Table 1) . Sometimes this might be supplemented by a graph that shows the evolution of each patient over time. This is particularly relevant when the treatment effects lapse and recurrences occur at variable times (Figure 1) .
For larger studies, data need to be amalgamated. An informative display is a table whose rows depict the range of possible scores for a given outcome and whose columns depict the numbers of patients who achieved those scores at different times. Such a display shows readers what the distribution of scores is at each point of assessment.
A second set of tables should show the magnitude of change of scores. For severity of pain, the percentage change in scores is particularly relevant and informative, for this foreshadows success rates. The table should have rows depicting the possible changes, from 100% improvement to no improvement, and the columns should show the numbers of patients achieving these changes. An additional row should show how many patients were rendered worse.
Having announced and displayed the raw outcome data, the Results should next report the descriptive statistics and the statistical significance of any changes over time. These might be incorporated into previous tables.
When applying descriptive statistics, authors should be mindful of the distributions of their data. If the data are not normally distributed, it is not appropriate to report means and standard deviations; median values and interquartile ranges may be more appropriate. Consequently, when data are compared, nonparametric statistical tests should be applied, instead of parametric ones.
Authors and readers alike should understand that statistical significance is a feature of the numbers used in a calculation; and although numbers may be significantly different, patients may not be so. Therefore, any statistical comparison should be supplemented by an assessment of clinical significance. Statistical significance alone does not constitute evidence of effectiveness. For a treatment to be considered effective, improvements must at least be clinically significant.
Once the data have been described, success rates should be reported for the several definitions of success outlined in the Methods. In the first instance, this should be done separately for each outcome measures. Each success rate should be accompanied by the 95% confidence intervals of the stated proportion.
In the second instance, success rates for composite outcomes should be reported. Although a given proportion of patients might report successful relief of pain and another proportion might report restoration of function, they may not necessarily be the same patients. Paradoxical outcomes can occur, such as improvement in function without relief of pain. Of interest to readers is the proportion of patients whose successful relief of pain is corroborated by simultaneous improvements in other domains of outcome. Reporting composite outcomes is straightforward when two outcomes are combined. This can be done in a table whose rows depict various grades of outcome for one variable, whose columns depict various grades of the second variable, and whose cells contain the number of patients who satisfy simultaneously the features of the respective intersecting column and row (Table 4) . This number can then be converted to a proportion.
More complex combinations do not lend themselves easily to tables in three or four dimensions. If worthwhile and informative, complex tables can be created (Table 5 ), but readers are not interested in every possible combination. They are interested only in the Figure 1 A graph of the pain scores over time of individual patients, otherwise shown in Table 1 . The patient identification number appears at the end of each line. The graph shows that although all patients improved at one month, thereafter they divided into those who maintained responses and those who did not. This division explains the lack of significant differences from inception at time 2 and time 3 shown in Table 1 . 
The P values pertain to differences from inception. The table shows readers that the pain scores at time 1 were significantly different from the scores at inception, but those at time 2 and time 3 were not. IQR ¼ interquartile range.
corroboration of success. To this end, all that may be required is to report how many patients who achieved successful outcomes in two variables also had a successful outcome in a third variable, or more. This can be done in text, without having to create a complex table.
Discussion
The content of the Discussion is defined less by what it should be and more by what it should not be. It should not be a restatement, or summary, of the results; those have just been announced in the preceding section. It should not be a repeat of the Introduction, for that repeats the question raised instead of addressing the answer provided by the study. Nor should the Discussion be a gratuitous essay on the pathology of the condition treated, or the mechanism of the treatment, or a review of other treatments. Too often, authors submit manuscripts in which having conducted a study is used as a pretext to lecture readers on these parenthetical topics. In this regard, the litmus test of a poor Discussion is how much of it could have been written without the study having been conducted.
The Discussion should strictly relate to the study itself.
The conclusion of the Discussion should not be ". . .and more research needs to be conducted;" that is self-evident and applies to any study. Rather, the study should have been a definitive contribution to the progress of Such a display allows readers to determine the success rate of treatment using whatever definition of success they wish to apply. For example, at one year, 24% of patients had complete relief of pain and 80% had at least 50% relief. At two years, 24% had complete relief but only 66% had at least 50% relief. The data shown reveal that while good outcomes remained stable, medium outcomes deteriorated slightly between one year and two years, which explains the slight deterioration in median score and interquartile range at two years shown in Table 2 . 
a" would be the number of patients who had complete relief of both back pain and leg pain. "c" would be the number who had complete relief of back pain but less than 50% relief of leg pain.
Science, even if it is a small contribution, or even if its results are negative. The study will have raised a question and should provide an answer to that question. The purpose of the Discussion then becomes an assessment of the integrity and validity of that answer. The internal validity and external validity of the study should be appraised.
Internal validity pertains to how well the methods used support the answer produced in order to render the answer convincing. The assessment of internal validity amounts to an appraisal of the extent to which any flaws, limitations, or biases affect the validity of the conclusions, their strength, or their precision. This invites a consideration of the validity of selection criteria, randomization, blinding, consistency of treatment, validity of assessment, and confounding factors such as comorbidity and co-interventions.
It is not enough simply to apologize for deficiencies in the study. Nor does simply listing the deficiencies exonerate the study. If there are serious deficiencies, the study should have been fixed before being submitted for publication. If the sample size was too small, the study should have continued until the sample was adequate. If controls were required, they should have been implemented when the study commenced. Apologies after the event do excuse the study for poor planning and execution. Apologies do not constitute a license for publishing an unworthy study.
Nevertheless, imperfections can apply to a study for various reasons. Individual flaws can then be assessed to determine the extent to which they bias the conclusion. Comparing the outcomes of the present study with those of others serves at least two purposes. Showing that the outcomes are similar to those of others shows that the present authors have been studying the same phenomenon that others have studied, which invites confidence that the present study is a valid representation of the treatment in question. Thereafter, the results of the present study serve to consolidate the evidence base for the treatment being tested.
If the results of the present study are at odds with the other literature, the authors have a duty to explain why they are so and why the present results should be preferred rather than ignored as an aberration due to some unrecognized, or undisclosed, flaw in the present study. Typically, the explanation would lie in stricter selection criteria or more rigorous application of the treatment.
When other literature is not available, for example, for a totally new treatment, authors need to be carefully circumspect about their results. Perceptive readers will be aware that, historically, early results typically overstate outcomes and that subsequent studies have typically achieved less flattering outcomes. Consequently, results that appear to be too good to be believed will be met with justified scepticism. Therefore, authors should take care not to overstate the results of first studies and rigorously explore all sources of possible bias.
Ultimately, external validity pertains to whether or not readers can expect to encounter the same outcomes reported in the present study if they adopted the treatment in question. Limiting factors include availability and cost of equipment necessary for the intervention, skills and training required, and the duration of learning. Otherwise, in this domain the characteristics of patients come to the fore. A pertinent issue is whether the treatment is applicable to all patients with a particular presenting complaint or if it applies only to highly selected patients with particular clinical, physical, and socioeconomic features, and who satisfy particular diagnostic criteria. For example, a treatment may not be a panacea for all patients with low back pain, but it might be highly successful for 5% of the population who satisfy the strict diagnostic criteria for an uncommon cause of pain. Conversely, a treatment might not be as "n1" is the number of patients who had complete relief of back pain and complete relief of leg pain, and who also restored normal physical functioning. "n9" is the number of patients who had more than 50% relief of back pain, but less than 50% relief of leg pain, but nevertheless restored normal physical functioning. "n4" is the number of patients who had complete relief of back pain and complete relief of leg pain, but did not restore normal function.
successful in patients who are difficult to treat for physical, socioeconomic, or psychological reasons.
In drawing their conclusions, authors should accord to readers the courtesy of dressing their conclusions with appropriate precautions. Stipulate in which patients and under what conditions might readers expect the outcomes reported in the present study-but equally important, in which patients has the treatment been shown not to work, or has it yet to be evaluated.
It is more honorable for authors to announce these limitations than to have critics raise them some time later when the published article is reviewed. The honor lies in recognizing and admitting limitations rather than hoping that no one will notice but later being exposed for having done so. Circumspect conclusions prevent premature, wholesale adoption of the treatment by impressionable readers, when such adoption is not justified by the evidence presented in the study.
